EUVIMEDEUVIMED entdecken
Crossref

HEC95468, a novel soluble guanylate cyclase stimulator, shows protection in the Dahl model of cardiorenal disorder

Fang-Yuan Wu, Jing Li, Min-Qiang Hu, Jun-Cheng Deng, Shan-Shan Liu, Man Xiang, Juan Wan, Sheng-Tian Cao, Ying-Lin Zuo, Bao-Hua Gu

European Journal of Pharmacology · 2025

DOI: 10.1016/j.ejphar.2025.178190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Fang-Yuan Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: HEC Research and Development Center, Sunshine Lake Pharma Co., Ltd, Dongguan, China. Hauptthemen laut MEDLINE: Soluble Guanylyl Cyclase, Cardio-Renal Syndrome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nitric oxide (NO) signaling plays a vital role in the regulation of cardiovascular and renal function. As the main receptor of NO, soluble guanylate cyclase (sGC) catalyzes the production of cyclic guanosine monophosphate (cGMP) via NO-mediated activation. In conditions of cardiorenal disorder with reduced NO bioavailability, NO-independent sGC stimulation could be an effective way to restore the downstream signaling. In the present study, we aimed to investigate the effects of HEC95468 [methyl (4,6-diamino-2-(7-fluoro-1-(2-fluorobenzyl)-1H-indazol-3-yl)pyrimidin-5-yl)carbamate], a clinical-stage sGC stimulator, in a rat model of cardiorenal damage. In vitro, HEC95468 was demonstrated to stimulate cGMP production with a slightly higher activity than the classical drug vericiguat. In vivo, HEC95468 was studied in the Dahl salt-sensitive (DSS) rats with a high-salt (HS) diet. HEC95468 treatment lowered the systolic and diastolic blood pressure, reduced the relative left ventricular free wall plus ventricular septum (LV + S) weight, prevented HS-induced increase of plasma NT-proANP and NP-proBNP levels, and improved left ventricular interstitial fibrosis. In terms of renal function, HEC95468 treatment decreased the urine protein creatinine ratio, reduced the serum level of KIM-1 and creatinine, as well as attenuating the progression of glomerulosclerosis, renal tubular damage and interstitial fibrosis. In addition, the survival rate was significantly improved in HEC95468-treated rats. These data suggest that HEC95468, a novel and potent sGC stimulator, demonstrates significant protective effects against cardiorenal disorder in HS-induced DSS rat model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Soluble Guanylyl CyclaseCardio-Renal SyndromeAnimalsRats, Inbred DahlMaleRatsDisease Models, AnimalCyclic GMPKidneyAtrial Natriuretic FactorBlood Pressure

Stichwörter der Autor:innen

Cardiorenal disorderDahl modelHEC95468Soluble guanylate cyclase stimulatorcGMP

Substanzen

Soluble Guanylyl CyclaseCyclic GMPAtrial Natriuretic Factor

Autor:innen und Institutionen

  • HEC Research and Development Center, Sunshine Lake Pharma Co., Ltd, Dongguan, China.
  • HEC Research and Development Center, Sunshine Lake Pharma Co., Ltd, Dongguan, China; State Key Laboratory of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd, Dongguan, China. Electronic addr…
  • HEC Research and Development Center, Sunshine Lake Pharma Co., Ltd, Dongguan, China; State Key Laboratory of Anti-Infective Drug Discovery and Development, Sunshine Lake Pharma Co., Ltd, Dongguan, China.

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Wu, F. Y., Li, J., Hu, M. Q., Deng, J. C., Liu, S. S., Xiang, M., Wan, J., Cao, S. T., Zuo, Y. L., & Gu, B. H. (2025). HEC95468, a novel soluble guanylate cyclase stimulator, shows protection in the Dahl model of cardiorenal disorder. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178190

Vancouver

Wu FY, Li J, Hu MQ, Deng JC, Liu SS, Xiang M, et al. HEC95468, a novel soluble guanylate cyclase stimulator, shows protection in the Dahl model of cardiorenal disorder. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.178190

BibTeX
@article{Wu2025,
  author = {Wu, Fang-Yuan and Li, Jing and Hu, Min-Qiang and Deng, Jun-Cheng and Liu, Shan-Shan and Xiang, Man and Wan, Juan and Cao, Sheng-Tian and Zuo, Ying-Lin and Gu, Bao-Hua},
  title = {HEC95468, a novel soluble guanylate cyclase stimulator, shows protection in the Dahl model of cardiorenal disorder},
  journal = {European Journal of Pharmacology},
  year = {2025},
  doi = {10.1016/j.ejphar.2025.178190}
}
Kostenlos starten →